Matthew P Kronman1, Jeffrey S Gerber2, Priya A Prasad2, Amanda L Adler3, Julie A Bass4, Jason G Newland5, Kavisha M Shah4, Danielle M Zerr3, Rui Feng6, Susan E Coffin7, Theoklis E Zaoutis7. 1. Division of Infectious Diseases, Seattle Children's Hospital, University of Washington School of Medicine matthew.kronman@seattlechildrens.org. 2. Division of Infectious Diseases, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine. 3. Division of Infectious Diseases, Seattle Children's Hospital, University of Washington School of Medicine. 4. Divisions of Gastroenterology. 5. Infectious Diseases, Children's Mercy Hospital and Clinics, University of Missouri-Kansas City School of Medicine. 6. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia. 7. Division of Infectious Diseases, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia.
Abstract
BACKGROUND: Antibiotics are often given for inflammatory bowel disease (IBD) exacerbations, but their use among pediatric inpatients has not been assessed. We aimed to validate administrative data for identifying hospitalizations for IBD exacerbation and to characterize antibiotic use for IBD exacerbations across children's hospitals. METHODS: To validate administrative data for identifying IBD exacerbation, we reviewed charts of 409 patients with IBD at 3 US tertiary care children's hospitals. Using the case definition with optimal test characteristics, we identified 3450 children with 5063 hospitalizations for IBD exacerbation at 36 children's hospitals between January 1, 2007 and December 31, 2009, excluding those with diagnosis codes for specific bacterial infections. We estimated predicted and expected hospital-specific antibiotic utilization rates using mixed-effects logistic regression, adjusting for patient- and hospital-level factors. RESULTS: Administrative codes for receipt of intravenous steroids or endoscopy provided 79% positive predictive value and 71% sensitivity for identifying hospitalizations for IBD exacerbation. Antibiotics were administered for ≥2 of the first 3 hospital days during 40.7% of IBD exacerbations in US children's hospitals; however, the proportion of patients receiving antibiotics varied significantly across hospitals from 27% to 71% (P < .001), despite adjustment for several patient- and hospital-level variables. Among those given antibiotics, the 3 most common regimens were metronidazole alone (26.9%), metronidazole with ciprofloxacin (10.3%), and ampicillin with gentamicin and metronidazole (7.0%). CONCLUSIONS: Significant variability exists in antibiotic use for children hospitalized with IBD exacerbation, which is unexplained by disease severity or hospital volume. Further study should determine the optimal antibiotic therapy for this condition.
BACKGROUND: Antibiotics are often given for inflammatory bowel disease (IBD) exacerbations, but their use among pediatric inpatients has not been assessed. We aimed to validate administrative data for identifying hospitalizations for IBD exacerbation and to characterize antibiotic use for IBD exacerbations across children's hospitals. METHODS: To validate administrative data for identifying IBD exacerbation, we reviewed charts of 409 patients with IBD at 3 US tertiary care children's hospitals. Using the case definition with optimal test characteristics, we identified 3450 children with 5063 hospitalizations for IBD exacerbation at 36 children's hospitals between January 1, 2007 and December 31, 2009, excluding those with diagnosis codes for specific bacterial infections. We estimated predicted and expected hospital-specific antibiotic utilization rates using mixed-effects logistic regression, adjusting for patient- and hospital-level factors. RESULTS: Administrative codes for receipt of intravenous steroids or endoscopy provided 79% positive predictive value and 71% sensitivity for identifying hospitalizations for IBD exacerbation. Antibiotics were administered for ≥2 of the first 3 hospital days during 40.7% of IBD exacerbations in US children's hospitals; however, the proportion of patients receiving antibiotics varied significantly across hospitals from 27% to 71% (P < .001), despite adjustment for several patient- and hospital-level variables. Among those given antibiotics, the 3 most common regimens were metronidazole alone (26.9%), metronidazole with ciprofloxacin (10.3%), and ampicillin with gentamicin and metronidazole (7.0%). CONCLUSIONS: Significant variability exists in antibiotic use for children hospitalized with IBD exacerbation, which is unexplained by disease severity or hospital volume. Further study should determine the optimal antibiotic therapy for this condition.
Authors: Charles N Bernstein; Michael Fried; J H Krabshuis; Henry Cohen; R Eliakim; Suleiman Fedail; Richard Gearry; K L Goh; Saheed Hamid; Aamir Ghafor Khan; A W LeMair; Qin Ouyang; J F Rey; Ajit Sood; Flavio Steinwurz; Ole O Thomsen; Alan Thomson; Gillian Watermeyer Journal: Inflamm Bowel Dis Date: 2010-01 Impact factor: 5.325
Authors: G J Mantzaris; K Petraki; E Archavlis; P Amberiadis; D Kourtessas; A Christidou; G Triantafyllou Journal: Scand J Gastroenterol Date: 2001-09 Impact factor: 2.423
Authors: Athos Bousvaros; Francisco Sylvester; Subra Kugathasan; Eva Szigethy; Claudio Fiocchi; Richard Colletti; Anthony Otley; Devendra Amre; George Ferry; Steven J Czinn; Judy B Splawski; Maria Oliva-Hemker; Jeffrey S Hyams; William A Faubion; Barbara S Kirschner; Marla C Dubinsky Journal: Inflamm Bowel Dis Date: 2006-09 Impact factor: 5.325
Authors: R L West; C J van der Woude; B E Hansen; R J F Felt-Bersma; A J P van Tilburg; J A G Drapers; E J Kuipers Journal: Aliment Pharmacol Ther Date: 2004-12 Impact factor: 8.171
Authors: Y Maeda; S C Ng; P Durdey; C Burt; J Torkington; P Kumar Dhruva Rao; J Mayberry; T Moshkovska; C D Stone; E Carapeti; C J Vaizey Journal: Br J Surg Date: 2010-09 Impact factor: 6.939
Authors: Kelvin T Thia; Uma Mahadevan; Brian G Feagan; Cindy Wong; Alan Cockeram; Alain Bitton; Charles N Bernstein; William J Sandborn Journal: Inflamm Bowel Dis Date: 2009-01 Impact factor: 5.325
Authors: Pamela F Weiss; Andrew J Klink; Kari Hexem; Jon M Burnham; Mary B Leonard; Ron Keren; Russell Localio; Chris Feudtner Journal: J Pediatr Date: 2009-07-29 Impact factor: 4.406
Authors: Chris Feudtner; James E Levin; Rajendu Srivastava; Denise M Goodman; Anthony D Slonim; Vidya Sharma; Samir S Shah; Susmita Pati; Crayton Fargason; Matt Hall Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Caitlin W Elgarten; Staci D Arnold; Yimei Li; Yuan-Shung V Huang; Marcie L Riches; Jeffrey S Gerber; Richard Aplenc; Wael Saber; Brian T Fisher Journal: Infect Control Hosp Epidemiol Date: 2018-05-08 Impact factor: 3.254
Authors: Colm B Collins; Derek Strassheim; Carol M Aherne; Alyson R Yeckes; Paul Jedlicka; Edwin F de Zoeten Journal: Inflamm Bowel Dis Date: 2014-04 Impact factor: 5.325
Authors: Faith D Ihekweazu; Tatiana Fofanova; Ryan Palacios; Avanthi Ajjarapu; Lina Karam; Adam M Vogel; J R Rodriguez; Richard Kellermayer Journal: J Pediatr Surg Date: 2020-02-03 Impact factor: 2.545